Notice 8 Aug 2025 investments, financial services, regulation, etf, securities, bitcoin, options trading

📈Cboe Proposes Options Trading Rules for VanEck Bitcoin ETF

The Cboe EDGX Exchange has proposed a rule change to permit the listing and trading of options on the VanEck Bitcoin ETF. This amendment expands the eligibility for Fund Shares, enhancing trading opportunities and providing investors with low-cost tools for managing Bitcoin exposure. The Exchange emphasizes the benefits of transparency and increased market activity facilitated by this development.

Learn More
Notice 8 Aug 2025 fracture mechanics, compliance, regulation, nuclear, licensing, business

⚛️Draft Regulatory Guide for Probabilistic Fracture Mechanics

The U.S. Nuclear Regulatory Commission (NRC) is issuing for public comment Revision 1 to draft Regulatory Guide (DG), DG-1422, "Preparing Probabilistic Fracture Mechanics Submittals." This DG is proposed Revision 1 to Regulatory Guide (RG) 1.245, "Preparing Probabilistic Fracture Mechanics Submittals." DG-1422, Revision 1, describes a framework to develop the contents of a licensing submittal that the staff of the NRC considers acceptable when performing probabilistic fracture mechanics (PFM) analyses in support of regulatory applications.

Learn More
Notice 8 Aug 2025 compliance, regulation, risk management, nuclear, safety, technology

⚛️NRC Draft Guide on Risk-Informed Change Evaluation for Nuclear Facilities

The U.S. Nuclear Regulatory Commission (NRC) is issuing for public comment a draft Regulatory Guide (DG), DG-1439, "Guidance for Technology-Inclusive Risk-Informed Change Evaluation." This DG is a proposed new regulatory guide that describes an approach that the staff of the NRC finds acceptable for using a technology-inclusive risk- informed change evaluation process for changes to a facility described in final safety analysis reports (as updated). Subject to the clarifications in Section C of this DG, the DG endorses the methodology described in Nuclear Energy Institute (NEI) 22-05, Revision 0, "Technology Inclusive Risk Informed Change Evaluation (TIRICE), Guidance for the Evaluation of Changes to Facilities Utilizing NEI 18- 04 and NEI 21-07," issued January 2024, for plants licensed using the guidance in NEI 18-04, "Risk-Informed Performance-Based Technology Inclusive Guidance for Non-Light Water Reactor Licensing Basis Development," and NEI 21-07, "Technology Inclusive Guidance for Non- Light Water Reactors, Safety Analysis Report Content for Applicants Using the NEI 18-04 Methodology."

Learn More
Notice 8 Aug 2025 financial market, regulation, securities exchange commission, etfs, bitcoin, options trading

📈Changes to Options Limits on Bitcoin ETFs Enhance Market Liquidity

The Securities and Exchange Commission has published a notice regarding proposed rule changes that amend position and exercise limits for options on specific Bitcoin-related ETFs. The amendments aim to increase liquidity in the market, decrease trading impediments, and enhance opportunities for investors and market makers to engage with these financial products.

Learn More
Notice 8 Aug 2025 options, trading, compliance, regulation, etf, securities, bitcoin

📈SEC Notice on Amending Position and Exercise Limits for Bitcoin ETFs

The SEC has published a notice regarding a proposed rule change by Nasdaq to increase the position and exercise limits for options on several bitcoin ETFs from 25,000 to 250,000 contracts. This change aims to foster a more competitive trading environment and enhance liquidity in the options market for these securities.

Learn More
Notice 8 Aug 2025 phosphate fertilizers, trade, regulation, russia, u.s. department of commerce, countervailing duties

📈Preliminary Results of Countervailing Duty Review on Phosphate Fertilizers

The U.S. Department of Commerce (Commerce) preliminarily determines that countervailable subsidies are being provided to Joint Stock Company Apatit (JSC Apatit), a producer and exporter of phosphate fertilizers from the Russian Federation (Russia). The period of review (POR) is January 1, 2023, through December 31, 2023. In addition, Commerce is rescinding this review with respect to Industrial Group Phosphorite LLC. Interested parties are invited to comment on these preliminary results.

Learn More
Rule 8 Aug 2025 fraud, gender-ideology, intergovernmental relations, health care, lawyers, compliance, department-of-defense, regulation, administrative practice and procedure, government employees, federal buildings and facilities, claims, courts

⚖️Department of Defense Rule Change on Gender Terminology in Litigation

In accordance with the Executive Order titled "Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government," this amendment rule removes text in this CFR part that promotes or otherwise inculcates gender ideology. This change is purely administrative.

Learn More
Notice 8 Aug 2025 grants, financial assistance, affordable housing, regulation, urban development, housing

🏘️HUD Grants Regulatory Waivers for Housing Programs in 2024

Section 106 of the Department of Housing and Urban Development Reform Act of 1989 (the HUD Reform Act) requires HUD to publish quarterly Federal Register notices of all regulatory waivers that HUD has approved. Each notice covers the quarterly period since the previous Federal Register notice. The purpose of this notice is to comply with the requirements of section 106 of the HUD Reform Act. This notice contains a list of regulatory waivers granted by HUD during the period beginning on November 1, 2024, and ending on December 31, 2024.

Learn More
Notice 8 Aug 2025 compliance, regulation, safety standards, environmental enforcement, oil and gas

🛢️Agency Collection Notice for Oil and Gas Well-Completion Operations

In accordance with the Paperwork Reduction Act (PRA) of 1995, the Bureau of Safety and Environmental Enforcement (BSEE) proposes to renew an information collection.

Learn More
Notice 8 Aug 2025 fda, public meeting, regulation, domestic production, pharmaceuticals, manufacturing

💊FDA Seeks Input on Onshoring Drug Manufacturing

The Food and Drug Administration (FDA, the Agency, or we) is announcing the establishment of a docket to solicit public comments on issues related to accelerating the establishment of new pharmaceutical manufacturing facilities in the United States. FDA is also announcing the following public meeting entitled "Onshoring Manufacturing of Drugs and Biological Products." At this meeting, FDA will present a draft framework that seeks to facilitate onshoring of pharmaceutical manufacturing. Participants will then engage in a guided discussion regarding the proposed framework, its strengths, weaknesses, and opportunities. The group will also discuss additional considerations that may help overcome current challenges faced by industry to onshoring the manufacturing of pharmaceuticals, including active pharmaceutical ingredients (APIs) and finished drug and biological products, and ideas and options within the bounds of FDA's statutory authority that could facilitate such onshoring of manufacturing.

Learn More